FDA panel votes against Pfizer rare disease drug Thu May 24, 2012 6:52pm EDT (Reuters) - Pfizer Inc said a U.S. health advisory panel voted against its drug to treat a rare neurodegenerative disease as the data did not show enough evidence of efficacy. The panel's recommendation will be considered by the U.S. Food and Drug Administration when it takes a decision on tafamidis, a relatively minor product for the world's largest drugmaker. Pfizer said the committee voted 13-4 against the drug. FDA staff on Tuesday recommended rejecting the drug saying the data did not prove that it worked well in treating the disease. Pfizer's shares closed at $22.14 on Thursday on the New York Stock Exchange. Reporting by Balaji Sridharan in Bangalore; Editing by Viraj Nair